title: The Primary Immune Deficiency Treatment Consortium: how can it improve definitive therapy for PID?
authors.affiliation: a UCSF Department of Pediatrics , Allergy, Immunology, and Blood and Marrow Transplant Division , San Francisco , CA , USA.
authors.forename: Morton J
authors.initials: MJ
authors.lastname: Cowan
mesh_terms: D006801:Humans; D015316:Genetic Therapy; D006105:Granulomatous Disease, Chronic / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D007153:Immunologic Deficiency Syndromes / Q000628:therapy; D054579:National Institute of Allergy and Infectious Diseases (U.S.); D010344:Patient Advocacy; D014481:United States; D014923:Wiskott-Aldrich Syndrome / Q000628:therapy; D015975:Consensus Development Conferences, NIH as Topic
keywords: Primary immune deficiency; SCID; Wiskott Aldrich syndrome; chronic granulomatous disease; enzyme replacement therapy; gene therapy; hematopoietic cell transplantation